Bristol Myers Squibb Company $BMY is Chiron Capital Management LLC’s Largest Position

Chiron Capital Management LLC lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 286,413 shares of the biopharmaceutical company’s stock after selling 13,195 shares during the quarter. Bristol Myers Squibb accounts for 11.5% of Chiron Capital Management LLC’s holdings, making the stock its biggest holding. Chiron Capital Management LLC’s holdings in Bristol Myers Squibb were worth $13,258,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in BMY. Brighton Jones LLC increased its holdings in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Bristol Myers Squibb during the first quarter valued at $2,298,000. Bailard Inc. raised its holdings in shares of Bristol Myers Squibb by 25.9% in the first quarter. Bailard Inc. now owns 7,160 shares of the biopharmaceutical company’s stock valued at $437,000 after acquiring an additional 1,472 shares in the last quarter. Kestra Private Wealth Services LLC lifted its stake in Bristol Myers Squibb by 1.9% in the first quarter. Kestra Private Wealth Services LLC now owns 170,104 shares of the biopharmaceutical company’s stock worth $10,375,000 after acquiring an additional 3,092 shares during the period. Finally, Elyxium Wealth LLC bought a new position in Bristol Myers Squibb during the 1st quarter worth about $256,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Down 4.0%

Bristol Myers Squibb stock opened at $46.67 on Monday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The stock has a market cap of $95.00 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The stock has a 50-day moving average of $45.34 and a two-hundred day moving average of $46.65. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BMY shares. Scotiabank began coverage on shares of Bristol Myers Squibb in a report on Thursday. They issued a “sector perform” rating and a $45.00 price target for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $54.58.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.